The endocannabinoid system: An overview

Frontiers in Behavioral Neuroscience

Volumn , Issue FEBRUARY 2012, 2012, Pages

  Battista, Natalia ^a,b   Tommaso, Monia Di ^a   Bari, Monica ^c   Maccarrone, Mauro ^a,b  

^a UNIVERSITY OF TERAMO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

2 arachidonoylglycerol; Anandamide; Endocannabinoids; Metabolic pathways; Signal transduction

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ADENYLATE CYCLASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; LIPOPROTEIN LIPASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NOLADIN ETHER; O 1966; O 3853; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PF 04457845; PHOSPHATIDYLINOSITOL 3 KINASE; PYRIMIDINECARBOXAMIDE DERIVATIVE; RIMONABANT; SR 141617A; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 158866; VANILLOID RECEPTOR 1; VIRODHAMINE;

ANXIETY; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; FATTY ACID METABOLISM; HUMAN; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OBESITY; OSTEOARTHRITIS; PAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SUICIDE; TRANSIENT ISCHEMIC ATTACK;

EID: 84857852475     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2012.00009     Document Type: Article

References (63)

1. Ahn, K., Smith, S.E., Liimatta, M.B., Beidler, D., Sadagopan, N., Dudley, D.T., Young, T., Wren, P., Zhang, Y., Swaney, S., Van Becelaere, K., Blankman, J.L., Nomura, D.K., Bhattachar, S.N., Stiff, C., Nomanbhoy, T.K., Weerapana, E., Johnson, D.S., and Cravatt, B.F. (2011). Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther 338, 114-124.
2. Alonso-Alconada, D., Alvarez, F.J., Alvarez, A., Mielgo, V.E., Goñi-de-Cerio, F., Rey-Santano, M.C., Caballero, A., Martinez-Orgado, J., and Hilario, E. (2010). The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic-ischemic injury in fetal lambs. Brain. Res 1362, 150-159.
3. Bari, M., Battista, N., Pirazzi, V., and Maccarrone, M (2011). The manifold actions of endocannabinoids on female and male reproductive events. Front. Biosci 16, 498-516.
4. Bari, M., Battista, N., Fezza, F., Finazzi Agrò, A., and Maccarrone, M. (2005). Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamideinduced apoptosis. J. Biol. Chem 280,12212-12220.
5. Beinfeld, M.C., and Connolly, K. (2001). Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci. Lett 301, 69-71.
6. Bortolato, M., Mangieri, R.A., Fu, J., Kim, J.H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., and Piomelli, D. (2007). Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 62, 1103-1110.
7. Centonze, D., Finazzi Agrò, A., Bernardi, G., and Maccarrone, M. (2007). The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends. Pharmacol. Sci 28, 180-187.
8. Christopoulou, F.D., and Kiortsis, D.N. (2011). An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J. Clin. Pharm. Ther 36, 10-18.
9. Clapper, J.R., Mangieri, R.A., and Piomelli, D. (2009). The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56, 235-243.
10. Cunha, P., Romão, A.M., Mascarenhas-Melo, F., Teixeira, H.M., and Reis, F. (2011). Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. J. Pharm. Bioallied. Sci 3, 350-360.
11. Dainese, E., Oddi, S., Bari, M., and Maccarrone, M. (2007). Modulation of the endocannabinoid system by lipid rafts. Curr. Med. Chem 14, 2702-2715.
12. Derkinderen, P., Ledent, C., Parmentier, M., and Girault, J.A. (2001). Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem 77, 957-960.
13. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
14. Di Marzo, V. (2008). CB(1) receptor antagonism: biological basis for metabolic effects. Drug. Discov. Today 13, 1026-1041.
15. Di Marzo, V., and De Petrocellis, L. (2010). Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr. Med. Chem 17, 1430-1449.
16. Dinh, T.P., Freund, T.F., and Piomelli D. (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids 121, 149-158.
17. Drmota, T., Greasley, P., and Groblewski, T. 2004. AstraZeneca WO04074844.
18. Fu, J., Bottegoni, G., Sasso, O., Bertorelli, R., Rocchia, W., Masetti, M., Guijarro, A., Lodola, A., Armirotti, A., Garau, G., Bandiera, T., Reggiani, A., Mor, M., Cavalli, A., and Piomelli, D. (2011). A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat. Neurosci In press.
19. Gertsch, J., Schoop, R., Kuenzle, U., and Suter, A. (2004). Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett 577, 563-569.
20. Ghozland, S., Matthes, H.W., Simonin, F., Filliol, D., Kieffer, B.L., and Maldonado, R. (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J. Neurosci 22, 1146-1154.
21. Giblin, G.M.P., Billinton, A., Briggs, M., Brown, A.J., Chessell, I.P., Clayton, N.M., Eatherton, A.J., Goldsmith, P., Haslam, C., Johnson, M.R., Mitchell, W.L., Naylor, A., Perboni, A., Slingsby, B.P., and Wilson, A.W. (2009). Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. J. Med. Chem 52, 5785-5788.
22. Giblin, G.M.P., O'Shaughnessy, C.T., Naylor, A., Mitchell, W.L., Eatherton, A.J., Slingsby, B.P., Rawlings, D.A., Goldsmith, P., Brown, A.J., Haslam, C.P., Clayton, N.M., Wilson, A.W., Chessell, I.P., Wittington, A.R., and Green, R. (2007). Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- 4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J. Med. Chem 50, 2597-2600.
23. Glucksmann, M. A., and Weich, N. 1999. Millennium Pharmaceuticals Inc., WO990023588.
24. Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro P.A., Brusco, A., and Uhl. G.R. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain. Res 1071, 10-23.
25. Hanus, L., Breuer, A., Tchillibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R.G., Ross, R.A., Mechoulam, R., and Fride, E. (1999). HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U S A 96, 14228-14233.
26. 2+ signaling and NFAT activation. FASEB J 23, 183-193.
27. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., and Rice, K.C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci 11, 563-583.
28. Kozak, K.R., Crews, B.C, Ray, J.L., Tai, H.H., Morrow, J.D., and Marnett L.J. (2001). Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J. Biol. Chem 276, 36993-36998.
29. Kozak, K.R., Crews, B.C., Morrow, J.D., Wang, L.H., Ma, H.Y., Weinander, R., Jakobsson, P.J., and Marnett L.J. (2002). Metabolism of the endocannabinoids, 2-arachidonoyglkycerol and anandamide, into prostaglandin, tromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem 277, 44877-44885.
30. Lanzafame, A.A., Guida, E., and Christopoulos, A. (2004). Effects of anandamide on the binding and signaling properties of M1 muscarinic acetylcholine receptors. Biochem. Pharmacol 68, 2207-2219.
31. Lauckner, J.E., Jensen, J.B., Chen, H. Y., Lu, H.C., Hille, B., and Mackie, K. (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA 105, 2699-2704.
32. Lichtman, A.H., and Chapman, V. (2001). A FAAH-fetched approach to treat osteoarthritis pain. Pain 152, 959-960.
33. Ligresti, A., Petrosino, S., and Di Marzo, V. (2009). From endocannabinoid profiling to "endocannabinoid therapeutics". Curr. Opin. Chem. Biol 13, 21-31.
34. López-Moreno, J.A., González-Cuevas, G., Moreno, G., and Navarro, M. (2008). The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict. Biol 13, 160-187.
35. Maccarrone, M., Dainese, E., and Oddi, S. (2010). Intracellular trafficking of anandamide: new concepts for signaling. Trends. Biochem. Sci 35, 601-608.
36. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J.J., Ramos, J.A., and Fuentes, J.A. (1999). Pharmacological and biochemical interactions between opioids and cannabinoids. Trends. Pharmacol. Sci 20, 287-294.
37. McKinney, M.K., and Cravatt, B.F. (2005). Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem 74, 411-432.
38. Molina-Holgado, E., Vela, J.M., Arévalo-Martín, A., Almazán, G., Molina-Holgado, F., Borrell, J., and Guaza, C. (2002). Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci 22, 9742-9753.
39. Moriconi, A., Cerbara, I., Maccarrone, M., and Topai, A. (2010). GPR55: Current knowledge and future perspectives of a purported Type-3 cannabinoid receptor. Curr. Med. Chem 17, 1411-29.
40. Muccioli G.G. (2010). Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug. Discov. Today 15, 474-483.
41. Munro, S., Munro, S., Thomas, K.L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral Receptor for cannabinoids. Nature 365, 61-65.
42. Nagayama, T., Sinor, A.D., Simon, R.P., Chen, J., Graham, S.H., Jin, K., and Greenberg, D.A. (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci 19, 2987-2995.
43. Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., and Sugiura, T. (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun 362, 928-934.
44. Oka, S.; Toshida, T., Maruyama, K., Nakajima, K., Yamashita, A., and Sugiura, T. (2009). 2-Arachidonoyl-sn-glycero-3-phosphoinositol: possible natural ligand for GPR55. J. Biochem 145, 13-20.
45. Okamoto, Y., Tsuboi, K., and Ueda, N. (2009). Enzymatic formation of anandamide. Vitam. Horm 81, 1-24.
46. Parmentier-Batteur, S., Jin, K., Mao, X.O., Xie, L., and Greenberg, D.A. (2002). Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci 22, 9771-9775.
47. 2. Pharmacol. Rev 62, 588-631.
48. Pertwee, R.G. (2007). GPR55: a new member of the cannabinoid receptor clan? Br. J. Pharmacol 152, 984-986.
49. Pertwee, R.G. (2006). Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol 147, S163-S171.
50. Pistis, M., and Melis, M. (2010). From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr. Med. Chem 17, 1450-1467.
51. Rouzer, C.A., and Marnett, L.J. (2011). Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem. Rev 111, 5899-5921.
52. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., and Greasley, P.J. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol 152, 1092-1101.
53. Sarnataro, D., Grimaldi, C., Pisanti, S., Gazzerro, P., Laezza, C., Zurzolo, C., and Bifulco, M. (2005). Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS. Lett 579, 6343-6349.
54. Tsuboi, K., Sun, Y.X., Okamoto, Y., Araki, N., Tonai, T., and Ueda N. (2005). Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem. 280, 11082-11092.
55. Ueda, N., Tsuboi, K., Uyama, T., and Ohnishi, T. (2011). Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. Biofactors 37, 1-7.
56. Van der Stelt, M., van Kuik, J.A., Bari, M., van Zadelhoff, G., Leeflang, B.R., Veldink, G.A., Finazzi Agrò, A., Vliegenthart, J.F., and Maccarrone, M. (2002). Oxygenated metabolites of anandamide and 2-arachidonoyl-glycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter and fatty acid amide hydrolase. J. Med. Chem 4, 3709-3720.
57. Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J.S., Marnett, L.J., Di Marzo, V., Pittman, Q.J., Patel, K.D., and Sharkey K.A. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332.
58. Viscomi, M.T., Oddi, S., Latini, L., Pasquariello, N., Florenzano, F., Bernardi, G., Molinari, M., and Maccarrone M. (2009). Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J. Neurosci 29, 4564-4570.
59. Wei, B.Q., Mikkelsen, T.S., McKinney, M.K., Lander, E.S., and Cravatt, B.F. (2006). A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem 281, 36569-36578.
60. Wise, A., and Brown, A.J. 2001. Glaxosmithkline. WO0186305.
61. Yao, B.B., Mukherjee, S., Fan, Y., Garrison, T.R., Daza, A.V., Grayson, G.K., Hooker, B.A., Dart, M.J., Sullivan, J.P., and Meyer, M.D. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br. J. Pharmacol 149, 145-154.
62. Zhang, M., Adler, M.W., Abood, M.E., Ganea. D., Jallo, J., and Tuma, R.F. (2009). CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc. Res 78, 86-94.
63. Zhang, M., Martin, B.R., Adler, M.W., Razdan, R.K., Jallo, J.I., and Tuma, R.F. (2007). Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood. Flow. Metab 27, 1387-1396.